{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:45:08Z","timestamp":1791265508440,"version":"4.1.0"},"reference-count":131,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. One dose of the vaccine is thought to give lifelong (35+ years) protective immunity, and neutralizing antibodies are the correlate of protection. Despite being a vaccine-preventable disease, YF remains a major public health burden, causing an estimated 109,000 severe infections and 51,000 deaths annually. There are issues of supply and demand for the vaccine, and outbreaks in 2016 and 2018 resulted in fractional dosing of the vaccine to meet demand. The World Health Organization (WHO) has established the \u201cEliminate Yellow Fever Epidemics\u201d (EYE) initiative to reduce the burden of YF over the next 10 years. As with most vaccines, the WHO has recommendations to assure the quality, safety, and efficacy of the YF vaccine. These require the use of live 17D vaccine only produced in embryonated chicken eggs, and safety evaluated in non-human primates only. Thus, any second-generation vaccines would require modification of WHO recommendations if they were to be used in endemic countries. There are multiple second-generation YF vaccine candidates in various stages of development that must be shown to be non-inferior to the current 17D vaccine in terms of safety and immunogenicity to progress through clinical trials to potential licensing. The historic 17D vaccine continues to shape the global vaccine landscape in its use in the generation of multiple licensed recombinant chimeric live vaccines and vaccine candidates, in which its structural protein genes are replaced with those of other viruses, such as dengue and Japanese encephalitis. There is no doubt that the YF 17D live-attenuated vaccine will continue to play a role in the development of new vaccines for YF, as well as potentially for many other pathogens.<\/jats:p>","DOI":"10.3390\/ph14090891","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T11:39:03Z","timestamp":1630496343000},"page":"891","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["The Present and Future of Yellow Fever Vaccines"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4841-2456","authenticated-orcid":false,"given":"Clairissa A.","family":"Hansen","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-4036, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-7448","authenticated-orcid":false,"given":"Alan D. T.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555-4036, USA"},{"name":"Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555-4036, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"ref_1","unstructured":"(2021, June 11). Transmission of Yellow Fever Virus, Available online: https:\/\/www.cdc.gov\/yellowfever\/transmission\/index.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(11)70147-5","article-title":"The revised global yellow fever risk map and recommendations for vaccination, 2010: Consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever","volume":"11","author":"Jentes","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","unstructured":"Plotkin, S.A., Orenstein, W.A., and Offit, P.A. (2013). 38-Yellow fever vaccine. Vaccines, W.B. Saunders. [6th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/14760584.2015.1083430","article-title":"Current status and future prospects of yellow fever vaccines","volume":"14","author":"Beck","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1016\/j.vaccine.2017.03.032","article-title":"Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease","volume":"35","author":"Barrett","year":"2017","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.aau8225","article-title":"The reemergence of yellow fever","volume":"361","author":"Barrett","year":"2018","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e64670","DOI":"10.7554\/eLife.64670","article-title":"The global burden of yellow fever","volume":"10","author":"Gaythorpe","year":"2021","journal-title":"Elife"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.3201\/eid2408.180588","article-title":"Phylogeny of Yellow Fever Virus, Uganda, 2016","volume":"24","author":"Hughes","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100858","DOI":"10.1016\/j.nmni.2021.100858","article-title":"The interplay between environmental factors, vector competence and vaccine immunodynamics as possible explanation of the 2019 yellow fever re-emergence in Nigeria","volume":"41","author":"Abdullahi","year":"2021","journal-title":"New Microbes New Infect."},{"key":"ref_10","unstructured":"WHO (2018). Epidemiological Update: Yellow Fever. 20 March 2018 Pan American Health Organization, World Health Organization."},{"key":"ref_11","unstructured":"World Health Organization (2018). A Global Strategy to Eliminate Yellow Fever Epidemics 2017\u20132026, World Health Organization."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/vim.2019.0107","article-title":"Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes","volume":"33","author":"Davis","year":"2020","journal-title":"Viral. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Staples, J.E., Monath, T.P., Gershman, M.D., and Barrett, A.D. (2018). Yellow fever vaccines. Plotkin\u2019s Vaccines, Elsevier.","DOI":"10.1016\/B978-0-323-35761-6.00063-8"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Van den Elsen, K., Quek, J.P., and Luo, D. (2021). Molecular Insights into the Flavivirus Replication Complex. Viruses, 13.","DOI":"10.3390\/v13060956"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.chom.2009.04.001","article-title":"Pathogenesis of flavivirus infections: Using and abusing the host cell","volume":"5","author":"Mazzon","year":"2009","journal-title":"Cell Host Microbe"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8867","DOI":"10.1128\/JVI.74.19.8867-8875.2000","article-title":"Substitutions at the putative receptor-binding site of an encephalitic flavivirus alter virulence and host cell tropism and reveal a role for glycosaminoglycans in entry","volume":"74","author":"Lee","year":"2000","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01956-15","DOI":"10.1128\/mBio.01956-15","article-title":"Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses","volume":"7","author":"Meertens","year":"2016","journal-title":"mBio"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12985-021-01611-2","article-title":"The key amino acids of E protein involved in early flavivirus infection: Viral entry","volume":"18","author":"Hu","year":"2021","journal-title":"Virol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.65.6.767","article-title":"The Effect of Prolonged Cultivation In Vitro Upon the Pathogenicity of Yellow Fever Virus","volume":"65","author":"Theiler","year":"1937","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.4269\/ajtmh.2006.75.1158","article-title":"Manipulation of the yellow fever virus non-structural genes 2A and 4B and the 3\u2019non-coding region to evaluate genetic determinants of viral dissemination from the Aedes aegypti midgut","volume":"75","author":"McElroy","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/infdis\/jit546","article-title":"Comparison of the live attenuated yellow fever vaccine 17D-204 strain to its virulent parental strain Asibi by deep sequencing","volume":"209","author":"Beck","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/infdis\/jit551","article-title":"Yellow fever vaccine attenuation revealed: Loss of diversity","volume":"209","author":"Tangy","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.qco.0000178823.28585.ad","article-title":"New developments in flavivirus vaccines with special attention to yellow fever","volume":"18","author":"Pugachev","year":"2005","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1038\/s41598-018-31085-2","article-title":"Analysis By Deep Sequencing of Discontinued Neurotropic Yellow Fever Vaccine Strains","volume":"8","author":"Beck","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20200063","DOI":"10.1098\/rsfs.2020.0063","article-title":"Testing the genomic stability of the Brazilian yellow fever vaccine strain using next-generation sequencing data","volume":"11","author":"Soares","year":"2021","journal-title":"Interface Focus"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.vaccine.2015.08.055","article-title":"Molecular characterization of the 17D-204 yellow fever vaccine","volume":"33","author":"Salmona","year":"2015","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1128\/JVI.02690-09","article-title":"Viral nucleic acids in live-attenuated vaccines: Detection of minority variants and an adventitious virus","volume":"84","author":"Victoria","year":"2010","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jviromet.2018.07.006","article-title":"Sanger-based sequencing technology for yellow fever vaccine genetic quality control","volume":"260","author":"Pestana","year":"2018","journal-title":"J. Virol. Methods"},{"key":"ref_29","unstructured":"World Health Organization (1945). Standards for the Manufacture and Control of Yellow Fever Vaccine. World Health Organization Epidemiological Bulletin, World Health Organization."},{"key":"ref_30","unstructured":"WHO (2016). International Health Regulations (2005), World Health Organization."},{"key":"ref_31","unstructured":"WHO (2013). Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. Annex 5, Standardization, WHO."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1286-4579(00)00288-4","article-title":"Stability-related studies on 17D yellow fever vaccine","volume":"2","author":"Perraut","year":"2000","journal-title":"Microbes Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","article-title":"Comparison of the immunogenicity and safety of two 17D yellow fever vaccines","volume":"60","author":"Lang","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Sanchez","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(20)32520-4","article-title":"Immunogenicity and safety of fractional doses of yellow fever vaccines: A randomised, double-blind, non-inferiority trial","volume":"397","author":"Kimathi","year":"2021","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/am.25.4.539-544.1973","article-title":"Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"ref_38","unstructured":"WHO (2003). Weekly Epidemiological Record: Yellow Fever Vaccine, World Health Organization."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wieten, R.W., Jonker, E.F., van Leeuwen, E.M., Remmerswaal, E.B., Ten Berge, I.J., de Visser, A.W., van Genderen, P.J., Goorhuis, A., Visser, L.G., and Grobusch, M.P. (2016). A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149871"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-020-0205-6","article-title":"Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection","volume":"5","author":"Staples","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMoa1710430","article-title":"Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak-Final Report","volume":"381","author":"Casey","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2005.12.055","article-title":"Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine","volume":"24","author":"Hepburn","year":"2006","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41598-017-00798-1","article-title":"Adaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccination","volume":"7","author":"Kongsgaard","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_45","unstructured":"ACIP (2015). Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Yellow Fever Vaccine Booster Doses."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1016\/j.vaccine.2019.09.051","article-title":"Duration of post-vaccination humoral immunity against yellow fever in children","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"ref_47","unstructured":"Sanofi Pasteur Inc (2016). Yellow Fever Vaccine: YF-VAX\u00ae Product Information, Sanofi Pasteur Inc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/597006","article-title":"Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients","volume":"48","author":"Veit","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/cix960","article-title":"Study, S.H.C., Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule","volume":"66","author":"Veit","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.cmi.2021.03.004","article-title":"Immunogenicity and duration of protection after yellow fever vaccine in people living with human immunodeficiency virus: A systematic review","volume":"27","author":"Martin","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.4049\/jimmunol.0902276","article-title":"Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells","volume":"183","author":"Xiang","year":"2009","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1084\/jem.20082292","article-title":"Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses","volume":"205","author":"Gaucher","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ni.1688","article-title":"Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1073\/pnas.1921388117","article-title":"Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine","volume":"117","author":"Wec","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1086\/590187","article-title":"Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes","volume":"198","author":"Pulendran","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1016\/j.vaccine.2007.08.061","article-title":"Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease","volume":"25","author":"Belsher","year":"2007","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/infdis\/169.3.512","article-title":"Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis","volume":"169","author":"Jennings","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_60","unstructured":"WHO (2013). Vaccines and vaccination against yellow fever. WHO position paper-June 2013. Wkly. Epidemiol. Rec., 88, 269\u2013283."},{"key":"ref_61","first-page":"647","article-title":"Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015","volume":"64","author":"Staples","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Campi-Azevedo, A.C., de Almeida Estevam, P., Coelho-Dos-Reis, J.G., Peruhype-Magalh\u00e3es, V., Villela-Rezende, G., Quaresma, P.F., Maia, M.e.L., Farias, R.H., Camacho, L.A., and Freire, M.a.S. (2014). Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-391"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"879","DOI":"10.4161\/hv.22982","article-title":"17DD yellow fever vaccine: A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study","volume":"9","author":"Martins","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"182","DOI":"10.12688\/wellcomeopenres.15579.1","article-title":"Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda","volume":"4","author":"Kimathi","year":"2019","journal-title":"Wellcome Open Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coviro.2016.03.010","article-title":"Animal models of yellow fever and their application in clinical research","volume":"18","author":"Julander","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Engelmann, F., Josset, L., Girke, T., Park, B., Barron, A., Dewane, J., Hammarlund, E., Lewis, A., Axthelm, M.K., and Slifka, M.K. (2014). Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003295"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/0022-1317-46-1-1","article-title":"The in vivo differentiation of strains of yellow fever virus in mice","volume":"46","author":"Fitzgeorge","year":"1980","journal-title":"J. Gen. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Meier, K.C., Gardner, C.L., Khoretonenko, M.V., Klimstra, W.B., and Ryman, K.D. (2009). A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000614"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1016\/j.vaccine.2012.03.003","article-title":"A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain","volume":"30","author":"Thibodeaux","year":"2012","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.vaccine.2021.02.033","article-title":"Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models","volume":"39","author":"Raynal","year":"2021","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4269\/ajtmh.2007.77.919","article-title":"Yellow fever 17-D vaccine is neurotropic and produces encephalitis in immunosuppressed hamsters","volume":"77","author":"Mateo","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies","volume":"183","author":"Tesh","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1128\/JVI.77.2.1462-1468.2003","article-title":"Molecular characterization of a hamster viscerotropic strain of yellow fever virus","volume":"77","author":"McArthur","year":"2003","journal-title":"J. Virol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.3389\/fimmu.2018.01756","article-title":"Immunogenicity and Protection after Vaccination with a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model","volume":"9","author":"Julander","year":"2018","journal-title":"Front Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1016\/j.vaccine.2019.04.077","article-title":"Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture","volume":"37","author":"Pato","year":"2019","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1016\/j.vaccine.2015.03.077","article-title":"An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures","volume":"33","author":"Pereira","year":"2015","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"212","DOI":"10.36233\/0507-4088-2020-65-4-212-217","article-title":"Development of inactivated cultural yellow fever vaccine","volume":"65","author":"Ivanov","year":"2020","journal-title":"Vopr. Virusol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0042-6822(92)90317-I","article-title":"Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis","volume":"187","author":"Pincus","year":"1992","journal-title":"Virology"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer, B., Holzer, G.W., Joachimsthaler, A., Coulibaly, S., Schwendinger, M., Crowe, B.A., Kreil, T.R., Barrett, P.N., and Falkner, F.G. (2011). Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024505"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Maciel, M., Cruz, F.a.S., Cordeiro, M.T., da Motta, M.A., Cassemiro, K.M., Maia, R.e.C., de Figueiredo, R.C., Galler, R., Freire, M.a.S., and August, J.T. (2015). A DNA vaccine against yellow fever virus: Development and evaluation. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003693"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.virol.2014.07.050","article-title":"Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice","volume":"468-470","author":"Tretyakova","year":"2014","journal-title":"Virology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1099\/jgv.0.000026","article-title":"Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone","volume":"96","author":"Jiang","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1080\/22221751.2019.1694394","article-title":"Limited evolution of the yellow fever virus 17d in a mouse infection model","volume":"8","author":"Kum","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1038\/s41598-020-61103-1","article-title":"Virus like Particles (VLP) as multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and Zika Virus","volume":"10","author":"Garg","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41551-019-0378-3","article-title":"Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging","volume":"3","author":"Lindsay","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"vey021","DOI":"10.1093\/ve\/vey021","article-title":"Exploratory re-encoding of yellow fever virus genome: New insights for the design of live-attenuated viruses","volume":"4","author":"Klitting","year":"2018","journal-title":"Virus. Evol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4269\/ajtmh.16-0293","article-title":"Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models","volume":"98","author":"Tottey","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An inactivated cell-culture vaccine against yellow fever","volume":"364","author":"Monath","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1099\/0022-1317-71-8-1697","article-title":"Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b","volume":"71","author":"Putnak","year":"1990","journal-title":"J. Gen. Virol."},{"key":"ref_91","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID) (2021). A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine with and Without Montanide ISA-720 Adjuvant in 18\u201345 Year Old Healthy Volunteers, NCT02743455."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.vaccine.2004.10.035","article-title":"Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: Yields, thermo and genetic stability, attenuation and immunogenicity","volume":"23","author":"Freire","year":"2005","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1517\/14712598.2012.704908","article-title":"Clinical development of IMOJEV \u00ae-a recombinant Japanese encephalitis chimeric vaccine (JE-CV)","volume":"12","author":"Appaiahgari","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.vaccine.2016.11.062","article-title":"Post-licensure, phase IV, safety study of a live attenuated Japanese encephalitis recombinant vaccine in children in Thailand","volume":"35","author":"Chotpitayasunondh","year":"2017","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: Development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults \u2265 50 years of age","volume":"30","author":"Dayan","year":"2012","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"13206","DOI":"10.1038\/s41598-018-31375-9","article-title":"Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine","volume":"8","author":"Goncalvez","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1080\/22221751.2020.1730709","article-title":"A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice","volume":"9","author":"Kum","year":"2020","journal-title":"Emerg. Microbes. Infect."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41541-018-0092-2","article-title":"A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice","volume":"3","author":"Kum","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8602","DOI":"10.1128\/JVI.79.13.8602-8613.2005","article-title":"Attenuation of recombinant yellow fever 17D viruses expressing foreign protein epitopes at the surface","volume":"79","author":"Bonaldo","year":"2005","journal-title":"J. Virol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Nogueira, R.T., Nogueira, A.R., Pereira, M.C., Rodrigues, M.M., Neves, P.C., Galler, R., and Bonaldo, M.C. (2013). Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS ONE, 8.","DOI":"10.1371\/annotation\/39b41d98-b117-41cf-b5de-b8486a67b1cd"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1128\/JVI.02255-09","article-title":"Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques","volume":"84","author":"Bonaldo","year":"2010","journal-title":"J. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins","volume":"345","author":"Bredenbeek","year":"2006","journal-title":"Virology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41586-020-3035-9","article-title":"A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate","volume":"590","author":"Vercruysse","year":"2021","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4161\/21645515.2014.983412","article-title":"Product review on the JE vaccine IXIARO","volume":"11","author":"Firbas","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1586\/14760584.2015.1061939","article-title":"The Vero cell-derived, inactivated, SA14-14-2 strain-based vaccine (Ixiaro) for prevention of Japanese encephalitis","volume":"14","author":"Erra","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4161\/hv.23802","article-title":"Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines","volume":"9","author":"Amicizia","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","article-title":"Flaviviruses and flavivirus vaccines","volume":"30","author":"Heinz","year":"2012","journal-title":"Vaccine"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1099\/vir.0.18860-0","article-title":"A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication","volume":"84","author":"Bredenbeek","year":"2003","journal-title":"J. Gen. Virol."},{"key":"ref_112","first-page":"285","article-title":"Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation","volume":"1","author":"Rice","year":"1989","journal-title":"New Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/14760584.2016.1175943","article-title":"DNA-launched live-attenuated vaccines for biodefense applications","volume":"15","author":"Pushko","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1002\/bit.27864","article-title":"Process intensification for the production of yellow fever virus-like particles as potential recombinant vaccine antigen","volume":"118","author":"Alvim","year":"2021","journal-title":"Biotechnol. Bioeng."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"ref_117","unstructured":"Kelland, K., and Heinrich, M. (2019). Epidemic group invests $34 million in potential vaccine printer tech. Healthc. Pharma, Available online: https:\/\/www.reuters.com\/article\/us-health-vaccines-curevac-idUSKCN1QG1MD."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1128\/JVI.80.7.3259-3272.2006","article-title":"Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region","volume":"80","author":"Burns","year":"2006","journal-title":"J. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"9687","DOI":"10.1128\/JVI.00738-06","article-title":"Reduction of the rate of poliovirus protein synthesis through large-scale codon deoptimization causes attenuation of viral virulence by lowering specific infectivity","volume":"80","author":"Mueller","year":"2006","journal-title":"J. Virol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pbi.2004.01.015","article-title":"Posttranslational modification of therapeutic proteins in plants","volume":"7","author":"Gomord","year":"2004","journal-title":"Curr. Opin. Plant. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e190187","DOI":"10.1590\/0074-02760190187","article-title":"Generation of Yellow Fever virus vaccine in skeletal muscle cells of chicken embryos","volume":"114","author":"Souza","year":"2019","journal-title":"Mem. Inst. Oswaldo. Cruz."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14760584.2016.1123097","article-title":"Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV\u00ae) in children","volume":"15","author":"Chokephaibulkit","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1586\/erv.11.7","article-title":"New Japanese encephalitis vaccines: Alternatives to production in mouse brain","volume":"10","author":"Halstead","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1586\/erv.10.139","article-title":"IMOJEV(\u00ae): A Yellow fever virus-based novel Japanese encephalitis vaccine","volume":"9","author":"Appaiahgari","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_125","unstructured":"Sanofi Pasteur (2014). Imojev \u00ae Package Insert, Sanofi Pasteur."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2017.1335201","article-title":"A recombinant live attenuated tetravalent vaccine for the prevention of dengue","volume":"16","author":"Guy","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/v5123048","article-title":"Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus","volume":"5","author":"Dayan","year":"2013","journal-title":"Viruses"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3201\/eid0812.020229","article-title":"Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model","volume":"8","author":"Tesh","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/infdis\/jiq074","article-title":"Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination","volume":"203","author":"Smith","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"taaa172","DOI":"10.1093\/jtm\/taaa172","article-title":"A clinician\u2032s perspective on yellow fever vaccine-associated neurotropic disease","volume":"27","author":"Lecomte","year":"2020","journal-title":"J. Travel. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/9\/891\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:54:11Z","timestamp":1760165651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/9\/891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":131,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ph14090891"],"URL":"https:\/\/doi.org\/10.3390\/ph14090891","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}